Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: 0.34 + release + 841  Related to the article below (Last Update: 8/4/2008)


Earthtimes (press release)
Superior Bancorp Tops $3 Billion in Assets; Announces Second ...
istockAnalyst.com, OR - Jul 28, 2008
This press release contains financial information determined by methods other than in accordance with US generally accepted accounting principles ('GAAP'). ...
Peoples Bancorp Inc. Announces Second Quarter Earnings Earthtimes (press release)
all 1,003 news articles »  SUPR - PEBO - PINK:PEBC
2003年留学工作概况
挖贝网, China - Jul 18, 2008
... 本科生19319人，占留学人员总数24.85%；硕士研究生3397人，占留学人员总数4.37%；博士研究生1637人，占留学人员总数2.11%；专科生263人，占留学人员总数0.34%。 ...
First M&F Corp. Reports a Loss But Fortifies Balance Sheet
Earthtimes (press release), UK - Jul 18, 2008
30 2008 2008 2007 2007 Per Common Share (diluted): Net income (0.05) 0.34 0.39 0.42 Cash dividends paid 0.13 0.13 0.13 0.13 Book value 15.38 15.83 15.45 ...
Source: Google News

Tetrandrine inhibits Ca2+ release-activated Ca2+ channels in vascular endothelial cells -
CY Kwan, YM Leung, TK Kwan, EE Daniel - Life Sciences, 2001 - Elsevier
... mM) 138 NaCl, 5.3 KCl, 0.8 MgSO 4 , 1.2 CaCl 2 , 0.44 KH 2 PO 4 , 0.34 Na 2 ... Life
Sciences 68 (2001) 841?847 845 ... 2 ]i via the blockade of Ca 2 -release acti- ...

Dominant role of N-type Ca2+ channels in evoked release of norepinephrine from sympathetic neurons -
LD Hirning, AP Fox, EW McCleskey, BM Olivera, SA … - Science, 1988 - sciencemag.org
... Release of Norepinephrine from Sympathetic Neurons ... importance in controlling
norepinephrine release was analyzed. N-type and L-type ...

Urine release in freely moving catheterised lobsters (Homarus americanus) with reference to feeding … -
T Breithaupt - Journal of Experimental Biology, 1999 - jeb.biologists.org
... 841 Urine output of lobsters ... The hourly probability of urine release by starved lobsters
ranged between 0.27 and 0.66 for individual lobsters (median 0.34; N=12 ...

[PDF] GaBoDS: The Garching-Bonn Deep Survey V. Data release of the ESO Deep-Public-Survey -
H Hildebrandt, T Erben, JP Dietrich, O Cordes, L … - Arxiv preprint astro-ph/0509882, 2005 - arxiv.org
... A summary of the data release and an outlook on projects carried out with the ... Their
properties are summarised in Table 2. The U-band filter ESO # 841 and the I ...
-

The Release of Ribonuclease into the Medium When Escherichia coli Cells Are Converted to … -
HC Neu, LA Heppel - Journal of Biological Chemistry, 1964 - ASBMB
... sidase, 0.5 to 0.7% leakage; RNase, 45 to 55% release; optical density at 260
rnp, 0.28 to 0.34; total protein, 0.15 to 0.17 mg per ml. ...

… Alkaline Phosphatase Activity and Transforming Growth Factor ?1 Release of Periodontal Ligament … -
MT Van der Pauw, T Van den Bos, V Everts, W … - Journal of Periodontology, 2000 - Am Acad Periodontology
... change when cultured on EMP-coated dishes (mean E/C ratio: 1.27 ? 0.34, n = 4).
EMP ... TGF 1 Release EMP coated in a concentration of 50 ?g/ml signifi- cantly ...

Oxyhemoglobin-induced cytotoxicity and arachidonic acid release in cultured bovine endothelial cells -
K Takenaka, NF Kassell, PL Foley, KS Lee - Stroke, 1993 - Am Heart Assoc
... Cytotoxicity and Arachidonic Acid Release in Cultured ... 1) cell morphology, 2) cell
density, and 3) the release of radiolabel from [3H]arachidonic acid-treated ...

[PDF] Performance and Efficiency Evaluation and Heat Release Study of an Outboard Marine Corporation …
CM Lee, KS Chun - NASA Technical Memorandum, 1987 - ntrs.nasa.gov
... Performance and Efficiency Evaluation and Heat Release Study of an Outboard Marine ...
Page 2. PERFORMANCE AND EFFICIENCY EVALUATION AND HEAT RELEASE STUDY OF AN ...

Antisense Oligonucleotide Inhibition Of Type II Phospholipase A2Expression, Release And Activity In … -
M Lappas, MJ Munns, RG King, GE Rice - Placenta, 2001 - Elsevier
... 3 , complementary to the base sequence 821- 841 of the ... PLA 2 enzymatic activity release,
and RNA was extracted ... (3 ? sodium chloride, 0.34 ? sodium citrate ...

… Releases ofEncarsia formosa (Hymenoptera: Aphelinidae): Are Higher Release Rates Necessarily Better … -
M Hoddle, R Van Driesche, J Sanderson - Biological Control, 1997 - Elsevier
... Mean numbers of adults per leaf ( SE) were 0.02 0.02 and 0.00 0.00, respectively,
for the low and high release rate trials (t value 1, df 1040, P 0.34). ...

Source: Google Scholar
 
 

Don't Move A Muscle: Evolutionary Insight Into Myogenesis

Article Date: 11 Dec 2006 - 9:00am (PST)
In a paper released online ahead of its scheduled December 15th publication date, Dr. Michael Krause (NIH) and colleagues detail the transcription network that drives muscle development in the roundworm C. elegans, and make a strong argument for an evolutionarily conserved program of myogenesis in all animals. Dr. Krause and colleagues demonstrate that three transcription factors - HLH-1, UNC-120 and HND-1 - redundantly control body wall muscle development in C. elegans. As the corresponding mammalian factors play important roles in directing vertebrate myogenesis, the authors propose that all animal muscle cell types (skeletal, smooth and cardiac muscle in vertebrates; and bodywall, smooth and cardiac/pharyngeal muscle in invertebrates) have arisen from a common ancestral precursor. Dr. Krause emphasizes that "understanding the redundancy built into worm muscle development reveals that the core transcriptional regulators of myogenesis are, as we would predict, conserved across animals."

Contact: Heather Cosel
Cold Spring Harbor Laboratory

Article continues below and (thank you)
 

Rochester Study Rolls Out RU-486 To Treat Uterine Fibroids

Article Date: 11 Dec 2006 - 8:00am (PST)
Low doses of the drug mifepristone shrink uterine fibroid tumors and greatly improve the quality of life in women who suffer from pain and heavy bleeding, according to a University of Rochester study published in the December Obstetrics and Gynecology journal.

Leiomyoma, the medical term for uterine fibroids, affects roughly half of all women aged 35 to 49. The non-cancerous tumors cause iron-deficiency anemia due to excessive menstrual bleeding, and deeply impact the quality of life for women who have this condition. Thousands of women annually opt for hysterectomies or have the tumors removed surgically because no other medical treatment has been proven effective, the study said.

"With no approved treatment for symptomatic fibroids, this study and its findings are very significant," said corresponding author Kevin Fiscella, M.D., M.P.H., of the Department of Family Medicine Research Program at the University of Rochester Medical Center. "Interestingly, this is the same drug that was recently shown to prevent breast cancer in a rat model. Federal funding for research related to mifepristone should be given a high priority."

 
Doctors have known from prior data that mifepristone, an antiprogestin, might help uterine fibroids. But the benefits had not been confirmed until now. The University of Rochester study is the first randomized, double blind, placebo-controlled trial of mifepristone, also known as RU-486, to establish that it can be safely used at low doses to treat uterine fibroids. Forty-two premenopausal women from western New York volunteered to participate in the clinical trial from March 2004 to March 2005.

Of the total, 22 women received mifepristone at 5 mg daily, and 20 women received an identical looking placebo pill daily, for six months. Doctors sought to evaluate physical changes as well as quality of life improvements. To assess the latter, they used a survey with a 100-point scale that asked questions such as: "During the past month, how distressed were you by: heavy bleeding during your menstrual period, feeling tightness or pressure in your pelvic area, or feeling fatigued""

Researchers assessed bleeding with a daily log and hemoglobin tests, and administered ultrasound and other tests to assess uterine volume and tumor size. Safety monitoring was conducted throughout the trial. The National Institute of Child Health and Human Development funded the study.

Results were dramatic. By the end of the study, for example, virtually every woman in the mifepristone group was certain she had been receiving the drug because of so many improvements -- despite the study's intentional design to keep everyone "blind" to the data and outcomes.

Here are some statistics cited by the study authors: n Although quality of life measurements were the same for both groups at the start of the study, the women on mifepristone reported a 135-percent improvement in quality of life after six months, compared to a 41-percent improvement in the placebo group. Symptoms decreased in both groups, but severity was significantly less in the mifepristone group.

n Blood loss also improved among women taking mifepristone. For example, hemoglobin levels went up in the treatment group from 12.0 to 13.5 g/DL, compared to a decrease in hemoglobin levels in the placebo group. At the start of the study, 11 of 22 women (50 percent) in the mifepristone group were anemic, but after six months of treatment only 2 or 22 women (9 percent) were anemic. In the placebo group anemia rose, with 9 of 22 women (45 percent) anemic at the start of the study, and 12 of 22 women (60 percent) anemic after six months.

"These very promising findings warrant replication through a large multicenter study," the authors wrote. Further studies should evaluate whether the drug can be safely taken for longer periods, and how long after stopping the drug would regrowth of fibroids occur. Side effects to the drug were uncommon during the University of Rochester study, but the authors noted that adverse events should be carefully monitored during follow-up studies.

A few deaths have been reported among women taking mifepristone at much higher doses (200-600 mg.) for pregnancy termination. However, medical authorities have not established a causal relationship between mifepristone and the deaths.

###

Contact: Leslie Orr
University of Rochester Medical Center
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page